Literature DB >> 32592069

Accuracy of radiomics for differentiating diffuse liver diseases on non-contrast CT.

Fatemeh Homayounieh1, Sanjay Saini2, Leila Mostafavi2, Ruhani Doda Khera2, Michael Sühling3, Bernhard Schmidt3, Ramandeep Singh2, Thomas Flohr3, Mannudeep K Kalra2.   

Abstract

PURPOSE: Radiomics help move cross-sectional imaging into the domain of quantitative imaging to assess the lesions, their stoma as well as in their temporal monitoring. We applied and assessed the accuracy of radiomics for differentiating healthy liver from diffuse liver diseases (cirrhosis, steatosis, amiodarone deposition, and iron overload) on non-contrast abdomen CT images in an institutional-reviewed board-approved, retrospective study.
METHODS: Our study included 300 adult patients (mean age 63 ± 16 years; 171 men, 129 women) who underwent non-contrast abdomen CT and had either a healthy liver (n = 100 patients) or an evidence of diffuse liver disease (n = 200). The diffuse liver diseases included steatosis (n = 50), cirrhosis (n = 50), hyperdense liver due to amiodarone deposition (n = 50), or iron overload (n = 50). We manually segmented the liver in one section at the level of the porta hepatis (all 300 patients) and then over the entire liver volume (50 patients). Radiomics were estimated for the liver, and statistical comparison was performed with multiple logistic regression and random forest classifier.
RESULTS: With random forest classifier, the AUC for radiomics ranged between 0.72 (iron overload vs. healthy liver) and 0.98 (hepatic steatosis vs. healthy liver) for differentiating diffuse liver disease from the healthy liver. Combined root mean square and gray-level co-occurrence matrix had the highest AUC (AUC:0.99, p < 0.01) for differentiating healthy liver from steatosis. Radiomics were more accurate for differentiating healthy liver from amiodarone (AUC:0.93) than from iron overload (AUC:0.79).
CONCLUSION: Radiomics enable differentiation of healthy liver from hepatic steatosis, cirrhosis, amiodarone deposition, and iron overload from a single section of non-contrast abdominal CT. The high accuracy of radiomics coupled with rapid segmentation of the region of interest, radiomics estimation, and statistical analyses within the same prototype makes a compelling case for bringing radiomics to clinical use for improving reporting in evaluation of healthy liver and diffuse liver diseases.

Entities:  

Keywords:  Amiodarone deposition; Cirrhotic liver; Hepatic steatosis; Iron overload; Non-contrast CT; Radiomics

Year:  2020        PMID: 32592069     DOI: 10.1007/s11548-020-02212-0

Source DB:  PubMed          Journal:  Int J Comput Assist Radiol Surg        ISSN: 1861-6410            Impact factor:   2.924


  4 in total

1.  Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study.

Authors:  Die Zhang; Yi Cao; Yi Sun; Xia Zhao; Cheng Peng; Jing Zhao; Xiaohui Bao; Lifei Wang; Chen Zhang
Journal:  Eur Radiol       Date:  2022-09-23       Impact factor: 7.034

2.  Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study.

Authors:  Zhong-Wei Chen; Kun Tang; You-Fan Zhao; Yang-Zong Chen; Liang-Jie Tang; Gang Li; Ou-Yang Huang; Xiao-Dong Wang; Giovanni Targher; Christopher D Byrne; Xiang-Wu Zheng; Ming-Hua Zheng
Journal:  Int J Med Sci       Date:  2021-09-07       Impact factor: 3.738

3.  Prediction of burden and management of renal calculi from whole kidney radiomics: a multicenter study.

Authors:  Sanjay Saini; Mannudeep K Kalra; Fatemeh Homayounieh; Ruhani Doda Khera; Bernardo Canedo Bizzo; Shadi Ebrahimian; Andrew Primak; Bernhard Schmidt
Journal:  Abdom Radiol (NY)       Date:  2020-11-26

4.  Stability of Liver Radiomics across Different 3D ROI Sizes-An MRI In Vivo Study.

Authors:  Laura J Jensen; Damon Kim; Thomas Elgeti; Ingo G Steffen; Bernd Hamm; Sebastian N Nagel
Journal:  Tomography       Date:  2021-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.